IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.2829
-0.0077 (-2.65%)
Mar 12, 2026, 1:36 PM EDT - Market open

IGC Pharma Income Statement

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
1.111.271.350.910.40.9
Revenue Growth (YoY)
-6.51%-5.50%47.64%129.47%-55.79%-77.95%
Cost of Revenue
0.60.650.610.470.20.79
Gross Profit
0.510.620.730.440.190.11
Selling, General & Admin
4.324.416.768.5513.297.91
Research & Development
4.293.663.773.462.330.93
Total Operating Expenses
8.618.0710.5312.0115.628.84
Operating Income
-8.09-7.45-9.8-11.57-15.43-8.72
Total Non-Operating Income (Expense)
1.650.33-3.20.070.41-0.09
Pretax Income
-6.45-7.12-13-11.51-15.02-8.81
Net Income
-6.45-7.12-13-11.51-15.02-8.81
Net Income to Common
-6.45-7.12-13-11.51-15.02-8.81
Shares Outstanding (Basic)
837759535042
Shares Outstanding (Diluted)
837759535042
Shares Change (YoY)
19.48%30.04%11.91%5.17%19.13%6.26%
EPS (Basic)
-0.07-0.09-0.22-0.22-0.30-0.21
EPS (Diluted)
-0.07-0.09-0.22-0.22-0.30-0.21
Free Cash Flow
-5.63-4.91-5.34-7.36-7.7-12.27
Free Cash Flow Per Share
-0.07-0.06-0.09-0.14-0.15-0.29
Gross Margin
46.20%48.70%54.50%48.52%48.87%12.58%
Operating Margin
-731.83%-585.84%-728.48%-1270.14%-3886.15%-971.49%
Profit Margin
-582.82%-560.27%-966.54%-1263.01%-3782.37%-981.18%
FCF Margin
-508.68%-386.07%-396.80%-807.57%-1939.04%-1366.37%
EBITDA
-7.52-6.83-9.16-10.91-14.78-8.25
EBITDA Margin
-680.20%-537.21%-681.12%-1198.02%-3722.17%-918.26%
EBIT
-8.09-7.45-9.8-11.57-15.43-8.72
EBIT Margin
-731.83%-585.84%-728.48%-1270.14%-3886.15%-971.49%
Updated Nov 14, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q